In addition, the carrier-free nanoplatform could be selectively triggered to release ICG and αPD-L1 by utilizing the tumor overexpressed MMP-2, thereby significantly enhancing the accuracy of αPD-L1-based checkpoint blockade therapy. The gene discussed is MMP2; the disease is neoplasm.